Retatrutide Chemical Specifications & Analytical Data

High Quality Retatrutide

Update Sept 29, 2026 The newest data on Retatrutide (Free signup to read document)

Update Sept 20, 2026 Eli Lilly to present new data on Foundayo, retatrutide, and eloraTZP at EASD 2026

Retatrutide is a triple-action peptide that targets GLP-1, GIP, and glucagon metabolic receptors, supporting astonishing fat loss, improved insulin sensitivity, and enhanced metabolic health.

• GLP-1 (Glucagon-Like Peptide-1) → Enhances insulin secretion, suppresses appetite, delays gastric emptying

• GIP (Glucose-Dependent Insulinotropic Polypeptide) → Boosts insulin response, improves insulin sensitivity, may support lipid metabolism

• Glucagon Receptor (GCGR) → Elevates energy expenditure, promotes fat oxidation, and may reduce liver fat

Recent Clinical trial

The TRIUMPH-1 milestone refers to the highly successful Phase 3 clinical trial results for retatrutide. It achieved historically unprecedented weight loss, at an average of 70.3 lbs (28.3%) of body weight over 80 weeks, at a dosage of 12mg per week. 45.3% of participants achieved ≥30% weight loss, a level long associated with bariatric surgery. See the latest clinical study design paper (October 2025) and the trial results (May 2026).

See our Research articles for a more in-depth look at the TRIUMPH study.